Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TACR2 | P21452 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14397598 | 0.89 | ALDH1A1 (0.49) | ALDH1A1KDM4EL3MBTL1LMNAHPGD | |
| SCHEMBL6850758 | 0.83 | ALDH1A1 (0.58) | ALDH1A1KDM4EL3MBTL1LMNAHPGD | |
| SCHEMBL1121517 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EL3MBTL1LMNAHPGD | |
| SCHEMBL1121407 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EL3MBTL1LMNAHPGD | |
| SCHEMBL1121574 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EL3MBTL1LMNAHPGD | |
| SCHEMBL1121698 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EL3MBTL1LMNAHPGD | |
| SCHEMBL1121310 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EL3MBTL1LMNAHPGD | |
| SCHEMBL1004449 | 0.82 | KDM4E (0.69) | ALDH1A1KDM4EL3MBTL1LMNAHPGD | |
| SCHEMBL13497712 | 0.81 | ALDH1A1 (0.51) | ALDH1A1KDM4EL3MBTL1LMNAHPGD | |
| SCHEMBL3572644 | 0.80 | ALDH1A1 (0.54) | ALDH1A1KDM4EL3MBTL1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-24 | — | — | US | disclosed |
| CN-119823001-A | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2025-04-15 | — | — | CN | disclosed |
| CN-114206832-B | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2025-04-04 | — | — | CN | disclosed |
| EP-4008405-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2022-06-08 | — | — | EP | disclosed |
| CN-114206832-A | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021020429-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | 大正製薬株式会社 | 2021-02-04 | — | — | WO | disclosed |
| CN-101679368-A | Aryl azoles, aryl diazole and benzimidizole derivatives | HOFFMANN LA ROCHE | 2010-03-24 | — | — | CN | disclosed |
| EP-2155718-A2 | ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148710-A2 | ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF SOMATOSTATINS RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008148710-A2 | ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF SOMATOSTATINS RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| US-20080306116-A1 | ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080306116-A1 | ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080306116-A1 | ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-12-11 | — | — | US | disclosed |
| WO-2007110340-A2 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | LPAR1, LPAR2, LPAR3 | ALDH1A1 1250/4885KDM4E 3851/4885L3MBTL1 4241/4885 |
| US-20080306116-A1 | ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES | SSTR5, NPY5R, SSTR3 | ALDH1A1 2068/4885KDM4E 2397/4885L3MBTL1 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.